Approximately 15% of invasive breast cancers are triple-negative breast cancers (TNBC) that lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions and usually exhibit a high pathological grade and more aggressive clinical behavior. This evidence concerns the gene ESR1 and invasive breast carcinoma.